1-20 of 21
Joel G. Turner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma

Jerald Noble, Frederick L. Locke, Constanza Savid-Frontera, Michael D. Jain, Joel G. Turner, Julieta Abraham Miranda, Thushara W Madanayake, Samira Naderinezhad, Salvatore Corallo, Meghan Menges, Kayla Reid, Timothy J Robinson
Journal: Blood
Blood (2023) 142 (Supplement 1): 3506.
https://doi.org/10.1182/blood-2023-185074
Published: 2023
Journal Articles

CAR-T Phenotype and Efficacy Is Impaired By Lymphoma-Associated CD39 + T Cells

Michael D. Jain, Xiaoqing Yu, Reginald Atkins, Joel G. Turner, Jerald Noble, Meghan Menges, Kayla Reid, Salvatore Corallo, Ling Cen, Sean J. Yoder, Julieta Abraham Miranda, Samira Naderinezhad, Hien Liu, Bijal D. Shah, Julio C Chavez, Erin Dean, Johannes Fahrmann, Neeraj Y. Saini, Samir Hanash, Rebecca S. Hesterberg, Paulo C. Rodriguez, John L. Cleveland, Marco Davila, Xuefeng Wang, Frederick L. Locke
Journal: Blood
Blood (2023) 142 (Supplement 1): 3500.
https://doi.org/10.1182/blood-2023-178113
Published: 2023
Journal Articles

Metabolically Flexible CAR T Cells (mfCAR-T), with Constitutive Expression of PGC-1α Resistant to Post Translational Modifications, Exhibit Superior Survival and Function in Vitro

Reginald M Atkins, PhD, Meghan A Menges, Alexis Bauer, BS, Joel G. Turner, PhD, Frederick L. Locke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30.
https://doi.org/10.1182/blood-2020-143217
Published: 2020
Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3314.
https://doi.org/10.1182/blood-2019-131321
Published: 2019
Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Cristina J Gasparetto, MD, Suzanne Lentzsch, MD, Gary J. Schiller, MD, William Bensinger, MD, Nizar Bahlis, MD, Heather J. Sutherland, MD PhD, Darrell J. White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Christine I Chen, MD, Aldo Del Col, Jatin J. Shah, MD, Jacqueline Jeha, Jean-Richard Saint-Martin, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Joel G. Turner, PhD, Daniel M Sullivan, MD, Brea Lipe, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 599.
https://doi.org/10.1182/blood-2018-99-117201
Published: 2018
Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3095.
https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095
Published: 2017
Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4509.
https://doi.org/10.1182/blood.V128.22.4509.4509
Published: 2016
Journal Articles

The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma

Yan Cui, MD, Joel G Turner, PhD, Jana L Dawson, BS, Juan A Gomez, BS, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Erkan Baloglu, PhD, William S. Dalton, PhD MD, Taiga Nishihori, MD, Daniel M Sullivan, MD
Journal: Blood
Blood (2016) 128 (22): 5662.
https://doi.org/10.1182/blood.V128.22.5662.5662
Published: 2016
Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2016) 128 (22): 3299.
https://doi.org/10.1182/blood.V128.22.3299.3299
Published: 2016
Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD
Journal: Blood
Blood (2015) 126 (23): 3048.
https://doi.org/10.1182/blood.V126.23.3048.3048
Published: 2015
Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2015) 126 (23): 1818.
https://doi.org/10.1182/blood.V126.23.1818.1818
Published: 2015
Journal Articles

Melphalan and XPO1 Inhibitor Combination Therapy for the Treatment of Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, MD PhD, Chris Cubitt, PhD, Rachid Baz, MD, Taiga Nishihori, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA, Daniel M Sullivan, MD
Journal: Blood
Blood (2014) 124 (21): 2084.
https://doi.org/10.1182/blood.V124.21.2084.2084
Published: 2014
Journal Articles

Targeting The Nuclear Export Signal In Multiple Myeloma

Joel G Turner, PhD, Thomas C Rowe, PhD, David Ostrov, PhD, Jana L Dawson, BS, Danielle Pernazza, PhD, Nicholas J Lawrence, Ph.D., Daniel M Sullivan, MD
Journal: Blood
Blood (2013) 122 (21): 1925.
https://doi.org/10.1182/blood.V122.21.1925.1925
Published: 2013
Journal Articles

Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease

Anandharaman Veerapathran, Joseph Pidala, Francisca Beato, Brian Betts, Jongphil Kim, Joel G. Turner, Marc K. Hellerstein, Xue-Zhong Yu, William Janssen, Claudio Anasetti
Journal: Blood
Blood (2013) 122 (13): 2251–2261.
https://doi.org/10.1182/blood-2013-03-492397
Published: 2013
Includes: Supplemental data
Journal Articles

Casein Kinase II Modulates Topoisomerase II Alpha Nuclear Export and Drug Sensitivity in Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Daniel M Sullivan, MD
Journal: Blood
Blood (2012) 120 (21): 4032.
https://doi.org/10.1182/blood.V120.21.4032.4032
Published: 2012
Journal Articles

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Joel G Turner, PhD, Thomas C Rowe, PhD, David Ostrov, Jana L Dawson, BS, Elizabeth Ciaravino, BS, Daniel Sullivan, MD
Journal: Blood
Blood (2010) 116 (21): 3006.
https://doi.org/10.1182/blood.V116.21.3006.3006
Published: 2010
Journal Articles

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Sharon Shacham, PhD, MBA, Joel G Turner, PhD, Raphael Nir, Giulio Draetta, Vincent Sandanayaka, Sharon Shechter, Michael Kauffman, Daniel Sullivan, MD
Journal: Blood
Blood (2010) 116 (21): 3012.
https://doi.org/10.1182/blood.V116.21.3012.3012
Published: 2010
Journal Articles

Blocking a Topoisomerase IIα Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells to Topoisomerase II Inhibitors.

Joel G. Turner, Ph.D., Thomas C. Rowe, PhD, David A. Ostrov, PhD, Elizabeth J. Ciaravino, Jana L. Gump, Daniel M. Sullivan
Journal: Blood
Blood (2009) 114 (22): 2850.
https://doi.org/10.1182/blood.V114.22.2850.2850
Published: 2009
Journal Articles

Intrinsic Drug Resistance in Multiple Myeloma to Doxorubicin Is Mediated by Soluble Factors

Daniel Sullivan, MD, MS, Jana L. Dawson, Elizabeth J. Ciaravino, Joel G. Turner, Ph.D.
Journal: Blood
Blood (2008) 112 (11): 5106.
https://doi.org/10.1182/blood.V112.11.5106.5106
Published: 2008
Journal Articles

ABCG2 expression, function, and promoter methylation in human multiple myeloma

Joel G. Turner, Jana L. Gump, Chunchun Zhang, James M. Cook, Douglas Marchion, Lori Hazlehurst, Pamela Munster, Michael J. Schell, William S. Dalton, Daniel M. Sullivan
Journal: Blood
Blood (2006) 108 (12): 3881–3889.
https://doi.org/10.1182/blood-2005-10-009084
Published: 2006